Corstasis Therapeutics

Executive Summary

Corstasis Therapeutics is a privately held, pre-revenue biotech company based in San Diego, California, founded in 2019. The company is focused on developing innovative, outpatient therapeutic solutions for fluid overload management in patients with congestive heart failure (CHF), liver disease, and kidney disease. By enabling patients to receive treatment in their own homes, Corstasis aims to reduce hospital readmissions, improve quality of life, and lower healthcare costs. The company's platform combines drug delivery technology with a patient-friendly design, targeting a significant unmet need in chronic disease management. With an aging population and rising prevalence of CHF and related conditions, the market for home-based fluid management is substantial and growing. Corstasis's approach could disrupt current standard of care, which often requires hospitalization for intravenous diuretics. The company's early-stage status and lack of public funding details suggest it is still in preclinical or early clinical development, with potential for significant upside if its technology proves effective and safe. The team's expertise and San Diego biotech ecosystem provide a supportive environment for advancement.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Announcement70% success
• Q2 2027Initiation of First-in-Human Phase 1 Trial50% success
• Q1 2027Strategic Partnership or Licensing Deal for Drug Delivery Platform40% success